KATIE QUICHOCHO: Open Payments
NPI 1245983840 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,906 in 82 payments from 22 companies in 2025. Trend: 2023 $92 · 2024 $1,987 · 2025 $1,906
Food & beverage: $1,857Education: $49
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 28 | $807 |
| Lilly USA, LLC | 6 | $102 |
| Pharming Healthcare, Inc. | 5 | $101 |
| Regeneron Healthcare Solutions, Inc. | 4 | $88 |
| Novartis Pharmaceuticals Corporation | 4 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $82 |
| BioCryst US Sales Co., LLC | 4 | $81 |
| Genentech USA, Inc. | 3 | $78 |
| CSL Behring | 4 | $68 |
| SANOFI-AVENTIS U.S. LLC | 1 | $49 |
Products named: DUPIXENT, EBGLYSS, RUCONEST, ORLADEYO, Xolair, Rhapsido, OCTAGAM IMMUNE GLOBULIN (HUMAN), Hizentra.
Industry payments across NE — which companies pay providers there.
